Imported from EML workbook.
Formulations: - Parenteral > General injections > IV: 500 µg in vial powder for injection Indications: - Malignant trophoblastic neoplasms of placenta - Unspecified malignant neoplasms of ill-defined or unspecified sites - Malignant neoplasms of kidney, except renal pelvis - Rhabdomyosarcoma primary site - Ewing sarcoma of bone and articular cartilage of unspecified sites Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride) Indications: - Acute myeloid leukaemia with recurrent genetic abnormalities - Lymphoid leukaemia, not elsewhere classified - Myeloid leukaemia Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL Indications: - Other specified malignant neoplasms of breast - Malignant neoplasms of breast - Malignant neoplasms of prostate - Unspecified malignant neoplasms of ill-defined or unspecified sites Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride) Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride) Indications: - Plasma cell myeloma Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride) Indications: - Kaposi sarcoma of unspecified primary site Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule Oral > Solid: 100 mg capsule Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate) Oral > Solid: 100 mg capsule; 50 mg capsule Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Burkitt lymphoma including Burkitt leukaemia - Ewing sarcoma of bone and articular cartilage of unspecified sites - Lymphoid leukaemia, not elsewhere classified - Myeloid leukaemia - Other specified malignant neoplasms of the ovary - Other specified malignant neoplasms of bronchus or lung - Germ cell tumour of testis - Malignant trophoblastic neoplasms of placenta - Malignant neoplasms of kidney, except renal pelvis - Osteosarcoma of bone and articular cartilage of unspecified sites - Hodgkin lymphoma - Retinoblastoma - Anaplastic large cell lymphoma, ALK-negative - Anaplastic large cell lymphoma, ALK-positive Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection Oral > Solid: 10 mg tablet (fludarabine phosphate) Indications: - Chronic lymphocytic leukaemia or small lymphocytic lymphoma Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule Parenteral > General injections > IV: 50 mg per mL in vial - Local > Topical > Ointment: 5% Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Malignant neoplasms of nasopharynx - Malignant neoplasm metastasis in large intestine - Malignant neoplasms of breast - Malignant neoplasms of rectum - Malignant neoplasms of colon - Plantar warts Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection Indications: - Other specified carcinomas of ovary - Other specified malignant neoplasms of bronchus or lung Source: EML workbook import
Formulations: - Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg - Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg Indications: - Squamous cell carcinoma of oropharynx - Chronic myeloid leukaemia, not elsewhere classified - Other specified sickle cell disorders or other haemoglobinopathies Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection Indications: - Other specified malignant neoplasms of the ovary - Germ cell tumour of testis - Ewing sarcoma of bone and articular cartilage of unspecified sites - Osteosarcoma of bone and articular cartilage of unspecified sites - Rhabdomyosarcoma primary site - Unspecified malignant neoplasms of ill-defined or unspecified sites - Burkitt lymphoma including Burkitt leukaemia - Malignant neoplasms of kidney, except renal pelvis - Anaplastic large cell lymphoma, ALK-negative - Anaplastic large cell lymphoma, ALK-positive Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial Indications: - Malignant neoplasm metastasis in large intestine - Malignant neoplasms of kidney, except renal pelvis - Rhabdomyosarcoma primary site Source: EML workbook import
Ready to amplify your rewards? Drop your email and we'll be in touch soon.
